Cloned (Comment) | Organism |
---|---|
overexpression of wild-type and mutant enzymes in Jurkat, Molt-4, and U87-MG cells | Homo sapiens |
Protein Variants | Comment | Organism |
---|---|---|
D133A | site-directed mutagenesis, the mutant is active with thymidine derivatives, in contrast to the wild-type enzyme | Homo sapiens |
additional information | mutants of dCK with rationally designed active sites, that make them thymidine-activating, are stably introduced into cells by recombinant lentiviral vectors. Transduced cells maintain growth kinetics and function. These dCK mutants efficiently activate bromovinyl-deoxyuridine, L-deoxythymidine, and L-deoxyuridine, which are otherwise not toxic to wild-type cells, overview. Mutant dCK-expressing Jurkat, Molt-4, and U87-MG cells could be efficiently eliminated in vitro and in xenogeneic leukemia and tumor models in vivo | Homo sapiens |
R104M | site-directed mutagenesis, the mutant is active with thymidine derivatives, in contrast to the wild-type enzyme | Homo sapiens |
R104M/D133A/S74E | site-directed mutagenesis, the mutant is active with thymidine derivatives, in contrast to the wild-type enzyme | Homo sapiens |
S74E | site-directed mutagenesis, the mutant is active with thymidine derivatives, in contrast to the wild-type enzyme | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Synonyms | Comment | Organism |
---|---|---|
dCK | - |
Homo sapiens |
deoxycytidine kinase | - |
Homo sapiens |
General Information | Comment | Organism |
---|---|---|
malfunction | mechanisms of cell killing by activated bromovinyl-deoxyuridine in Jurkat cells expressing thymidine-activating deoxycytidine kinase, cell fate control gene therapy strategy, overview. Tumor formation is repressed by dCK-based cell fate control gene therapy strategy in vivo in a xenogeneic murine model and thymidine-activating dCK mutant increased survival in a stringent model of T cell leukemia | Homo sapiens |